QuarterHawk — Equity ResearchQuarterHawk — Equity Research

biote Corp. (BTMD)

Healthcare

No action
Fundamental
3
Sentiment
3
Technical
2

Do Nothing: avgDollarVolume20 ~$109,014 is far below the $5,000,000 liquidity floor (last 3 regular sessions ~$46,170/day vs the $1,500,000 recent-liquidity floor), so no order can be worked at a fair price; a pullback limit is additionally countertrend (price 1.03 < SMA50 1.20 with MACD -0.04 < 0), and while a breakout stop above the settled 1.11 high would give R/R ~1.54, it fails the same liquidity gate.

Analysis as of 2026-11-12· more than 2 trading days ago

Company overview

Biote Corp. supports medical practices focusing on hormone optimization, offering a system for Biote-certified professionals to address hormone, vitamin, and mineral imbalances. The company provides bioidentical hormone treatments, dietary supplements, and sterile kits for hormone pellet insertion.

Fundamental

fair
Fundamental3
Mixed fundamentals

Biote Corp.'s fundamentals are mixed, with low valuation multiples but high uncertainty due to recall and legal issues.

Recent SEC filings show BTMD coming off a profitable FY2025 but posting a markedly weaker 1H2026 tied to a voluntary recall and elevated legal costs (revenue down year-over-year and results swinging to a net loss). Liquidity includes ~$11.2M cash at 6/30/2026, a $125M term loan, and disclosed revolver capacity, with covenant compliance and no going‑concern language, but also negative equity and prior credit-agreement waiver history. Valuation multiples look very low (P/E ~6.3, EV/EBITDA ~4.6, EV/Sales ~1.0), yet the setup remains high‑uncertainty until revenue/margins and legal/regulatory noise stabilize.

Sentiment

fair
Sentiment3
Forming sentiment

Sentiment is mixed, with insider buying partially offset by recall-related challenges.

Executive-Chairman insider buying (announced, bullish) partially offsets a voluntary-recall overhang and a break-even Q2 print (both announced); media sentiment delta indeterminate after three baseline-extraction failures; moderate red-flag cap applied for conflicting catalyst signals (insider buying vs. recall).

Technical

weak
Technical2
Countertrend bounce

The technical setup shows a fading bounce within a downtrend, with no bullish setup identified.

Chart quality 2/5 — weak bearish, bounce-only. Price 1.03 sits below the SMA20 (1.10), SMA50 (1.20), SMA200 (1.78) and both EMAs (9: 1.09, 21: 1.12) in a downtrend that has run from the 2.26 area in early August; the 11-04 spike to 1.23 has fully retraced to a 1.02 low. RSI14 41.26 and Williams %R -84.03 show no oversold reversal impulse, MACD -0.04/-0.04/0.00 is flat at the zero line, and ADX 17.74 is falling from 25.8 — trend energy is dissipating without a bullish turn. ATR14 0.10 is 9.7% of price (very high volatility). No bullish setup; the name is additionally disqualified on liquidity.

You’re looking at 2026-11-12 — more than 2 trading days ago.

Subscribers saw this then, and see today’s score, verdict and trade plan now.

Not financial advice. For informational and educational purposes only.